Lunesta Regulatory Status: US, EU, Canada, UK

Eszopiclone, sold in the United States under the brand name Lunesta, is an oral cyclopyrrolone hypnotic approved by the FDA for insomnia. It is not sold anywhere in the European Union, in Canada, or in the United Kingdom. Those markets instead use zopiclone, the racemic parent compound from which eszopiclone was isolated as the single (S)-enantiomer. This is a regulatory and commercial gap, not a safety finding against eszopiclone: no European, Canadian, or UK agency has issued a public statement rejecting eszopiclone on safety grounds, and the reason a marketing application was never filed in those regions appears to be economic rather than clinical.

What is established about the US approval

The FDA approved eszopiclone on December 15, 2004, under NDA 021476, for the treatment of insomnia, and its label does not carry the 35-day duration limit that had applied to some earlier hypnotics. The current prescribing information is available from the FDA's own drug label archive FDA label, and it remains the primary source for dosing, pharmacokinetics, and warnings.

The DEA classifies eszopiclone as Schedule IV, the same tier as zolpidem and zaleplon, reflecting recognized but comparatively lower abuse potential relative to Schedule III agents. In 2014 the FDA lowered the recommended starting dose from 2 mg to 1 mg after post-marketing surveillance identified next-morning impairment, a concern that disproportionately affected older adults. In 2019, the FDA added a boxed warning to eszopiclone and other GABA-modulating hypnotics for complex sleep behaviors, including sleepwalking and sleep-driving. These are FDA regulatory actions and can be verified directly against the label and the agency's drug safety communications page.

The efficacy program that supported approval included a multi-month randomized placebo-controlled trial in adults with chronic insomnia, commonly cited as demonstrating sustained improvement in sleep latency and wake time after sleep onset without evidence of tolerance over extended nightly use. The specific effect sizes attributed to that trial in earlier drafts of this article could not be verified against a located primary source and are omitted here pending confirmation; a reader who needs exact trial numbers should consult the FDA label's clinical studies section or a peer-reviewed insomnia pharmacotherapy review rather than take secondary figures at face value.

Why the EU, Canada, and the UK use zopiclone instead

Zopiclone reached European markets, starting with France, in the mid-1980s and was already an entrenched, inexpensive generic hypnotic across EU member states by the time Sepracor developed and filed for eszopiclone approval in the US in the early 2000s. For a single-enantiomer drug derived from an already-approved racemate (a "chiral switch"), EU, UK, and Canadian regulators generally expect the applicant to demonstrate a clinically meaningful advantage over the parent compound, whether in efficacy, side-effect burden, or therapeutic index. Sepracor does not appear to have submitted a marketing authorization application to the EMA, Health Canada, or the MHRA for eszopiclone.

This is best understood as a commercial decision under a regulatory constraint, not a rejection. With zopiclone already cheap and generic in these markets, the incremental clinical benefit needed to justify a new, separately patented single-enantiomer product may not have cleared the bar those agencies set for chiral-switch approvals, and the manufacturer had a much stronger commercial case to pursue in the US, where zopiclone itself had never been approved and eszopiclone could enter as a genuinely new option. The European Sleep Research Society's 2017 insomnia guideline lists zopiclone, alongside zolpidem and short-acting benzodiazepine receptor agonists, as a first-line short-term pharmacologic option; it does not evaluate eszopiclone because the drug has no European indication to evaluate. NICE's guideline on insomnia (CG191) similarly addresses zopiclone and zolpidem, restricting hypnotic use to short courses after non-drug measures have failed NICE CG191.

A specific attributed quotation from a named guideline author, present in an earlier version of this material, could not be verified against a located source and has been removed rather than repeated as fact.

Canada: the zopiclone default

Health Canada has not approved eszopiclone. Zopiclone has been available in Canada since the mid-1980s under the brand Imovane and as generics, and it is scheduled in the same controlled-substance tier as eszopiclone is in the US. Canadian insomnia guidance generally favors cognitive behavioral therapy for insomnia (CBT-I) as first-line care and reserves hypnotics like zopiclone for short-term, cautious use. Precise figures on Canadian pricing or dispensing volume that appeared in an earlier draft could not be verified against a primary institutional source and have been removed; a reader who needs current Canadian prescribing volumes should consult the Canadian Institute for Health Information directly CIHI rather than rely on an unsourced number here.

United Kingdom: zopiclone under NHS prescribing

The MHRA has not licensed eszopiclone. Zopiclone holds a UK marketing authorization and was reclassified from an unscheduled prescription medicine to a Class C controlled drug under the Misuse of Drugs Act in 2014, following an Advisory Council on the Misuse of Drugs review of misuse and diversion. NICE's CG191 guideline recommends zopiclone or zolpidem only after sleep hygiene measures and CBT-I have been tried or are unavailable, and it caps recommended courses at two to four weeks NICE CG191. Specific dispensing volumes and post-reclassification prescribing trend figures cited in an earlier draft could not be verified against a located NHS or gov.uk publication and have been removed; anyone who needs current English dispensing data should query NHS Business Services Authority data directly rather than rely on a secondhand figure.

How eszopiclone works, and what is and is not established about its pharmacology

Eszopiclone is a cyclopyrrolone that binds the benzodiazepine site on GABA-A receptors, enhancing inhibitory chloride conductance. It is chemically distinct from benzodiazepines despite sharing this binding site. According to the FDA label, peak plasma concentration occurs roughly 1 to 1.5 hours after an oral dose, the elimination half-life is on the order of 6 hours in healthy adults, and a high-fat meal delays absorption, which is why the label recommends taking the drug on an empty stomach close to bedtime FDA label.

What is plausible but not firmly established from the material available here: claims about a specific receptor-subunit selectivity profile (alpha-2/alpha-3 versus alpha-1) and precise binding-affinity numbers for eszopiclone versus its (R)-enantiomer appeared in an earlier draft attached to sources that could not be verified. The general concept that cyclopyrrolones and Z-drugs differ from one another in subunit selectivity is discussed in the pharmacology literature, but a reader relying on a specific Ki value for clinical or comparative purposes should verify it against a current pharmacology review rather than this page.

Because the S-enantiomer carries most of the hypnotic activity of racemic zopiclone, eszopiclone at a given milligram dose is generally considered pharmacologically comparable to roughly double that dose of zopiclone, which is the basis for the rough dose correspondences some formularies publish (see below). This is a structural and pharmacologic inference, not a validated bioequivalence finding, and it should not be used to self-convert a dose.

Rough dose correspondence between eszopiclone and zopiclone

Some national formularies, including the British National Formulary, publish approximate equivalence guidance for clinicians managing patients who move between an eszopiclone-prescribing country and a zopiclone-prescribing one BNF:

• Eszopiclone 1 mg is roughly comparable to zopiclone 2 to 2.5 mg
• Eszopiclone 2 mg is roughly comparable to zopiclone 5 mg
• Eszopiclone 3 mg is roughly comparable to zopiclone 7.5 mg

These are clinical approximations, not exact pharmacokinetic conversions, and the (R)-enantiomer in zopiclone does have some weak activity that may contribute to differences in side effects such as taste disturbance. A patient moving between countries should have their prescriber make the switch rather than converting the dose themselves.

Japan: the other market where eszopiclone itself is approved

The Pharmaceuticals and Medical Devices Agency approved eszopiclone in Japan in 2012, and it is marketed there by Eisai as Lunesta in the same 1 mg, 2 mg, and 3 mg strengths used in the US PMDA. Japan and the United States are, on current information, the only major regulatory markets where eszopiclone itself (rather than the racemate) holds an approval.

Abuse potential and scheduling differences across countries

All Z-drugs, including zopiclone, eszopiclone, zolpidem, and zaleplon, carry recognized dependence and abuse liability, and scheduling differences between countries mainly reflect local prescribing history and monitoring rather than a difference in the underlying pharmacology. In the US, eszopiclone is Schedule IV and carries the 2019 boxed warning for complex sleep behaviors described above. In the UK, zopiclone became a Class C controlled drug in 2014 after an Advisory Council on the Misuse of Drugs review found evidence of diversion and recreational use; before that, zopiclone had been the only Z-drug not scheduled under the Misuse of Drugs Act. Canada schedules zopiclone at a comparable controlled-substance tier to the US scheduling of eszopiclone. Specific numeric trends in poisoning calls or emergency department visits that appeared in an earlier draft could not be traced to a verifiable primary report and have been omitted; readers interested in current Canadian substance-related poisoning surveillance should consult the Canadian Institute for Health Information directly CIHI.

What is established, what is plausible, and what is not established

Established: eszopiclone has FDA approval in the US and PMDA approval in Japan; it has no marketing authorization in the EU, Canada, or the UK; zopiclone is the racemic parent compound available in those markets; both drugs are controlled substances in every jurisdiction discussed here; the FDA lowered the eszopiclone starting dose in 2014 and added a boxed warning for complex sleep behaviors in 2019.

Plausible but not confirmed here: that the absence of a European, Canadian, or UK filing was driven specifically by cost-effectiveness modeling rather than some other commercial or strategic reason; the exact numeric dose-response and adverse-event figures from the original approval trials, which require verification against the primary published studies or the FDA's own clinical review rather than being repeated as fixed figures on this page.

Not established from available sources: any specific receptor-binding affinity numbers distinguishing eszopiclone from its (R)-enantiomer; any current-year dispensing volume, price, or poisoning-call statistic for the UK, Canada, or elsewhere; the previously included quotation attributed to a named guideline author, which has been removed because it could not be verified.

When to talk to a clinician rather than rely on this page

This article describes regulatory status and general pharmacology. It is not dosing guidance. Anyone currently taking eszopiclone or zopiclone who is relocating, traveling internationally, or experiencing side effects such as pronounced next-day sedation, unusual behavior during sleep, or signs of dependence should discuss it with the prescribing clinician rather than adjusting the dose or substituting one drug for the other independently. Sudden discontinuation after prolonged nightly use, or new neurological or psychiatric symptoms, warrants prompt medical attention rather than a wait-and-see approach.

Decision guide: what to do if eszopiclone is not available where you are